new studies on glp 1 Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans: Cell Reports Medicine GLP-1 agonists' safety during pregnancy

Findings from recently completed trials indicate that a GLP-1 RA-induced increase in HR, regardless of magnitude, does not present an increased cardiovascular risk for subjects with T2DM, although a pronounced increase in HR may be associated with adverse clinical outcomes in those with advanced heart failure

Alcohol can trigger inflammation, and GLP-1 therapies carry warnings related to pancreatic risk

A separate prospective study of approximately 200 adults (Haines et al., presented at the Endocrine Society, 2025) combining GLP-1 therapy with structured protein guidance and resistance training education found participants lost about 13% body weight but only about 3% muscle mass on average

[54] The drug decreases mimicks the hormone glucagon-like peptide-1 (GLP-1), an incretin